Lipoic acid
- Generic Name
- Lipoic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14O2S2
- CAS Number
- 1200-22-2
- Unique Ingredient Identifier
- VLL71EBS9Z
- Background
A vitamin-like antioxidant.
- Indication
For nutritional supplementation, also for treating dietary shortage or imbalance.
- Associated Conditions
- Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- Dietary and Nutritional Therapies, Nutritional supplementation
Topiramate and Pregabalin Reduce Migraine Frequency and Intensity in Pediatric Patients
• A network meta-analysis reveals that pregabalin and topiramate, with or without vitamin D3, significantly reduce migraine frequency in children and adolescents.
• The study highlights that pregabalin resulted in a 63% reduction in migraine frequency, which increased to 88% when combined with vitamin D supplementation.
• Flunarizine, levetiracetam, riboflavin, cinnarizine, and amitriptyline also showed potential in reducing migraine frequency, though further studies are needed for confirmation.
• Amitriptyline, topiramate and valproate were associated with the greatest adverse events compared to placebo, underscoring the need for careful monitoring.
OCTOPUS Trial Shows Progress in Evaluating Alpha-Lipoic Acid and Metformin for Progressive MS
• The OCTOPUS trial, a multi-arm study, is assessing R/S alpha-lipoic acid and metformin for progressive multiple sclerosis, aiming to enroll 375 participants in its first stage.
• As of March 2024, 189 participants have been randomized, with a majority diagnosed with secondary progressive MS and an average disease duration of 20.6 years.
• The OCTOPUS trial seeks to address the significant unmet need for effective treatments for progressive MS, where ocrelizumab is currently the only FDA-approved option.
Extended-Course Nirmatrelvir/Ritonavir Shows Promise in Treating Long COVID Symptoms
A series of case studies highlights the potential benefits of extended-course nirmatrelvir/ritonavir treatment for individuals suffering from Long COVID, with some patients reporting significant improvements in symptoms. The treatment, typically used for acute COVID-19 infections, was administered outside of the acute phase, offering new insights into managing Long COVID.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath